Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 9/20 | 0.69 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4175953 | 0.82 | AR (1.00) | ARSLC22A12PGR | |
| SCHEMBL13779687 | 0.80 | AR (0.59) | ARSLC22A12MRGPRX4 | |
| SCHEMBL4206255 | 0.78 | AR (0.57) | ARSLC22A12MRGPRX4PGRTRPV4 | |
| SCHEMBL177449 | 0.77 | AR (0.53) | ARMRGPRX4PGRTRPV4 | |
| SCHEMBL4172657 | 0.76 | AR (0.68) | ARSLC22A12PGR | |
| SCHEMBL5289804 | 0.75 | PPARA (0.44) | ARTSHR | |
| SCHEMBL4192800 | 0.75 | AR (0.52) | ARMRGPRX4S1PR3 | |
| SCHEMBL4188116 | 0.73 | AR (0.68) | ARSLC22A12PGR | |
| SCHEMBL27376804 | 0.73 | AR (0.52) | ARMRGPRX4PGRTRPV4 | |
| SCHEMBL1592873 | 0.72 | NISCH (0.47) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197642-A1 | Androgen modulators | WARNER-LAMBERT COMPANY LLC | 2007-08-23 | — | — | US | claimed |
| EP-1740533-A1 | ANDROGEN MODULATORS | Warner-Lambert Company LLC (US) | 2007-01-10 | — | — | EP | claimed |
| WO-2005102990-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-03 | — | — | WO | claimed |
| US-7473711-B2 | Androgen modulators | PFIZER INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-20070197642-A1 | Androgen modulators | WARNER-LAMBERT COMPANY LLC | 2007-08-23 | — | — | US | disclosed |
| EP-1740533-A1 | ANDROGEN MODULATORS | Warner-Lambert Company LLC (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005102990-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197642-A1 | Androgen modulators | CYP17A1, NR5A1, SHBG | AR 4/4885SLC22A12 3245/4885MRGPRX4 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.